Patients and data collection
primary peritoneal cancer
FALLOPIAN TUBE, RESIDUAL DISEASE, ADVERSE EVENTS, EPITHELIAL OVARIAN CANCER
Eligible patients aged between 18 and 70 years, with newly diagnosed stage III epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer, with optimal or complete primary debulking (residual disease ≤ 1 cm), a World Health Organisation (WHO) performance status of 0–2, normal blood counts and adequate renal and hepatic function, who were planned to receive adjuvant intraperitoneal chemotherapy were enrolled.Monitoring of haemoglobin, haematocrit, erythrocyte, thrombocyte and white blood cell (WBC) counts with differential classification of neutrophils, lymphocytes, monocytes, eosinophils and basophils, together with monitoring of liver panel, renal function and electrolytes took place as part of routine clinical care prior to the start and prior to day 8 of every treatment cycle. The occurrence of adverse events, other than laboratory abnormalities, that required a dose reduction or discontinuation of therapy were extracted from the medical record.The study protocol was approved by the institutional ethics committee Arnhem-Nijmegen (Nijmegen) and was compliant with the Declaration of Helsinki. All patients provided written informed consent before entering the study. The study was conducted at the Radboud University Medical Center in Nijmegen, the Netherlands.